Kala Bio, INC Schedule 13G passive stakes

LifeSci Capital LLC and its managers, Andrew McDonald and Michael Rice, have reported a beneficial ownership of 7.9% in KALA BIO, Inc. common stock.

Oxford Finance LLC has reported a 16.5% beneficial ownership stake in KALA BIO, Inc., holding 1,620,000 shares of common stock.

Point72 Asset Management, along with Point72 Capital Advisors Inc. and Steven A. Cohen, reported a 0.0% beneficial ownership in KALA BIO, Inc. as of September 30, 2025.

Perceptive Advisors and related entities report 0% beneficial ownership in KALA BIO, Inc. common stock.

Cormorant Asset Management, LP and Bihua Chen filed an amended Schedule 13G, reporting zero beneficial ownership in KALA BIO, Inc.'s common stock as of September 30, 2025.

Baker Bros. Advisors and affiliates have reclassified their KALA BIO, Inc. stake to a passive 9.99% ownership, relinquishing board nomination rights.

Point72 Asset Management, along with Point72 Capital Advisors Inc. and Steven A. Cohen, has disclosed a 6.7% beneficial ownership stake in KALA BIO, Inc.

Perceptive Advisors, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have reported a 7.7% beneficial ownership stake in KALA BIO, Inc.

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have filed an amended Schedule 13G indicating they no longer beneficially own any shares of KALA BIO, Inc. common stock as of March 31, 2025.

ADAR1 Capital Management, LLC, along with its general partner and manager Daniel Schneeberger, has disclosed a beneficial ownership of 4.91% in KALA BIO, Inc. as of December 31, 2024.

Cormorant Asset Management, LP and Bihua Chen have disclosed a 9.99% beneficial ownership stake in KALA BIO, Inc., totaling 609,027 shares of common stock.